Identifier
Created
Classification
Origin
05TAIPEI4160
2005-10-12 22:52:00
CONFIDENTIAL
American Institute Taiwan, Taipei
Cable title:  

TAIWAN MAY PRODUCE OSELTAMAVIR IF AVIAN INFLUENZA

Tags:  AMED EIND TBIO TW 
pdf how-to read a cable
This record is a partial extract of the original cable. The full text of the original cable is not available.

122252Z Oct 05
C O N F I D E N T I A L SECTION 01 OF 02 TAIPEI 004160 

SIPDIS

STATE FOR EAP/TC, ALSO PASS AIW/W

E.O. 12958: DECL: 10/12/2010
TAGS: AMED EIND TBIO TW
SUBJECT: TAIWAN MAY PRODUCE OSELTAMAVIR IF AVIAN INFLUENZA
BREAKS OUT

REF: TAIPEI 3742

Classified By: AIT DIRECTOR DOUGLAS PAAL FOR REASONS 1.5 (b) (d)

C O N F I D E N T I A L SECTION 01 OF 02 TAIPEI 004160

SIPDIS

STATE FOR EAP/TC, ALSO PASS AIW/W

E.O. 12958: DECL: 10/12/2010
TAGS: AMED EIND TBIO TW
SUBJECT: TAIWAN MAY PRODUCE OSELTAMAVIR IF AVIAN INFLUENZA
BREAKS OUT

REF: TAIPEI 3742

Classified By: AIT DIRECTOR DOUGLAS PAAL FOR REASONS 1.5 (b) (d)


1. (C) Reftel reported on indications from senior officials
that Taiwan may be capable of and intending to develop the
ability to produce the anti-viral drug oseltamavir (trade
name tamiflu),with or without permission from the patent
holder, in the event of a breakout in Taiwan of human to
human transmission of avian influenza (AI).


2. (U) According to an October 12 press report in the
Liberty Times, Dr. Steven Kuo (shui-sung),Director of
Taiwan's Center for Disease Control (TCDC) said that Taiwan
should manufacture oseltamavir if avian influenza breaks out
on Taiwan in order to protect the island's population.
According to the press reports, Kuo said that Taiwan has the
capability to produce the drug and should do so if needed
whether patent holder Roche provides permission or not.
Separate news reports on October 12 cite Taipei City Animal
Control officials as warning the public not to have contact
with live poultry because of the danger of avian influenza.
Animal Control officials state that 14 Asian nations have
been infected with AI and that now only South Korea, Japan
and Taiwan are not infected.

Production Plans
--------------

3. (C) TCDC Director Kuo confirmed the news reports to AIT
on October 12. He said that he had also given an interview
to the New York Times on the same subject. Kuo went on to
emphasize that Taiwan is struggling to strike an appropriate
balance between the need to manufacture oseltamavir for
national security needs and appropriate intellectual property
rights protection. He noted that Taiwan's patent law
provides for compulsory licensing, which also requires
compensation be paid to the rightsholders. He confirmed that
Taiwan has established a task force to examine the issues
involved on both the technical and legal fronts. He said
that both Roche and Gillette have claims on the rights to
oseltamavir. According to Kuo, Taiwan now has drug
stockpiles for less than 1% of the population and seeks to
have sufficient dosages to treat 10% of the population. He
said Taiwan now has contracts with Roche to supply by mid
2006 sufficient stocks to treat another 3-4% of the
population. If Taiwan invokes compulsory licensing and
produces its own supplies, Kuo said the goal would be to
produce enough medicine to supply another 5% of the
population. Thus, Taiwan would meet the WHO recommendation
to have drug stockpiles to treat 10% of the total population.
In concluding his remarks, Dr. Kuo emphasized that to date,
no Taiwan firm has started to produce the drug. He said that
Taiwan is simply not yet at the point where it is ready to
engage in discussions with Roche on the issue or to begin
production. The raw materials for the drug would be imported
from China. Kuo said that Taiwan has been importing the raw
materials for many years and would only need to significantly
increase its imports in order to be able to produce the
oseltamavir.

Patent Law Provides for Compulsory Licensing
--------------

4. (U) Taiwan's patent law includes a compulsory licensing
provision that officials could invoke to compel licensing
authority from Roche to produce the drug in event of a
declared emergency. Article 76 of Taiwan's patent law allows
the Patent Authority to grant a right of compulsory licensing
to satisfy domestic market requirements under three
conditions: 1) national emergency; 2) non-profit use of a
patent to enhance public welfare or 3) when an applicant has
failed to reach a licensing agreement with the rights holder
under reasonable commercial terms and conditions within a
considerable period of time. Under Taiwan's patent law,
Roche would receive "appropriate compensation" for the
emergency use of its intellectual property. In case of a
dispute over the amount of compensation, Taiwan's Patent
Authority would determine the compensation. Taiwan's
Intellectual Property Office confirmed to AIT/T the
compulsory licensing provisions in its Law. To AIT/T's
knowledge, this provision has only been used once and that
was to secure licensing rights under provision number 3 above
in the information technology industry.


5. (C) Comment: We believe that Taiwan has been carefully
planning how to increase its supply of oseltamavir and is
prepared to invoke compulsory licensing provisions to achieve
its goal of having sufficient stocks of the drug to treat 10%
of its population. MOFA Vice Minister Kau Ying-mao assured
the Director on October 12 that Taiwan is sensitive to this
issue, and will work to accommodate the rightsholders. End
Comment.
PAAL